Effects of Immunosuppression on Circulating Adeno-Associated Virus Capsid-Specific T cells in Humans

Abstract

In humans adeno-associated virus (AAV)-mediated gene transfer is followed by expansion of AAV capsid-specific T cells, evidence of cell damage, and loss of transgene product expression, implicating immunological rejection of vector-transduced cells, which may be prevented by immunosuppressive drugs. We undertook this study to assess the effect of immunosuppression (IS) used for organ transplantation on immune responses to AAV capsid antigens. Recipients of liver or kidney transplants were tested before and 4 weeks after induction of IS in comparison with matched samples from healthy human adults and an additional cohort with comorbid conditions similar to those of the transplant patients. Our data show that transplant patients and comorbid control subjects have markedly higher frequencies of circulating AAV capsid-specific T cells compared with healthy adults. On average, IS resulted in a reduction of AAV-specific CD4⁺ T cells, whereas numbers of circulating CD8⁺ effector and central memory T cells tended to increase. Independent of the type of transplant or the IS regimens, the trend of AAV capsid-specific T cell responses after drug treatment varied; in some patients responses were unaffected whereas others showed decreases or even pronounced increases, casting doubt on the usefulness of prophylactic IS for AAV vector recipients.

Get full access to this article

View all access options for this article.

References

Araki

, Turner

A.P.

, Shaffer

V.O.

et al. 2009. mTOR regulates memory CD8 T-cell differentiation. Nature, 460:108–112.

Ardehali

, Volmar

, Roberts

et al. 2001. Fatal disseminated adenoviral infection in a renal transplant patient. Transplantation, 71:998–999.

Atchison

R.W.

, Casto

B.C.

, Hammon

W.M.

1965. Adenovirus-associated defective virus particles. Science, 149:754–756.

Gao

G.P.

, Alvira

M.R.

, Wang

et al. 2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A., 99:11854–11859.

Boutin

, Monteilhet

, Veron

et al. 2010. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors. Hum. Gene Ther., 21:704–712.

Chen

, Wu

, Yang

et al. 2006. Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy. Mol. Ther., 13:260–269.

Glenn

1981. Cytomegalovirus infections following renal transplantation. Rev. Infect Dis., 3:1151–1178.

Grigoryev

Y.A.

, Kurian

S.M.

, Avnur

et al. 2010. Deconvoluting post-transplant immunity: Cell subset-specific mapping reveals pathways for activation and expansion of memory T, monocytes and B cells. PLoS One, 5:e13358.

Gummert

J.F.

, Ikonen

, Morris

R.E.

1999. Newer immunosuppressive drugs: A review. J. Am. Soc. Nephrol., 10:1366–1380.

10.

Hickman

S.P.

, Turka

L.A.

2005. Homeostatic T cell proliferation as a barrier to T cell tolerance. Philos. Trans. R. Soc. Lond. B Biol. Sci., 360:1713–1721.

11.

Kiani

, Rao

, Aramburu

2000. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity, 12:359–372.

12.

, Lasaro

M.O.

, Jia

et al. 2011. Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates. Mol. Ther., 19:2021–30.

13.

Lucas

K.G.

, Pollok

K.E.

, Emanuel

D.J.

1997. Post-transplant EBV induced lymphoproliferative disorders. Leuk. Lymphoma, 25:1–8.

14.

Manno

C.S.

, Pierce

G.F.

, Arruda

V.R.

et al. 2006. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med., 12:342–347.

15.

Mingozzi

, Maus

M.V.

, Hui

D.J.

et al. 2007. CD8⁺ T-cell responses to adeno-associated virus capsid in humans. Nat. Med., 13:419–422.

16.

Mingozzi

, Meulenberg

J.J.

, Hui

D.J.

et al. 2009. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood, 114:2077–2086.

17.

Mingozzi

, High

K.A.

2011. Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges. Nat. Rev. Genet., 12:341–355.

18.

Mollet

, Sadat-Sowti

, Duntze

et al. 1998. CD8^hi+CD57⁺ T lymphocytes are enriched in antigen-specific T cells capable of down-modulating cytotoxic activity. Int. Immunol., 10:311–323.

19.

Mueller

, Flotte

T.R.

2008. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther., 15:858–863.

20.

Nathwani

A.C.

, Gray

J.T.

, McIntosh

et al. 2007. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood, 109:1414–1421.

21.

Nathwani

A.C.

, Tuddenham

E.G.

, Rangarajan

et al. 2011. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med., 365:2357–2365.

22.

Ritter

M.L.

, Pirofski

2009. Mycophenolate mofetil: Effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl. Infect. Dis., 11:290–297.

23.

Roederer

, Nozzi

J.L.

, Nason

M.C.

2011. SPICE: Exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A, 79A:167–174.

24.

Schnepp

B.C.

, Jensen

R.L.

, Chen

C.L.

et al. 2005. Characterization of adeno-associated virus genomes isolated from human tissues. J. Virol., 79:14793–14803.

25.

Scroggs

M.W.

, Wolfe

J.A.

, Bollinger

R.R.

, Sanfilippo

1987. Causes of death in renal transplant recipients. A review of autopsy findings from 1966 through 1985. Arch. Pathol. Lab. Med., 111:983–987.

26.

Sehgal

S.N.

2003. Sirolimus: Its discovery, biological properties, and mechanism of action. Transplant. Proc., 35:7S–14S.

27.

Shroff

, Mehta

R.S.

, Chinen

et al. 2012. Presentation of atopic disease in a large cohort of pediatric liver transplant recipients. Pediatr. Transplant., 16:379–384.

28.

Vandenberghe

L.H.

, Wilson

J.M.

, Gao

2009. Tailoring the AAV vector capsid for gene therapy. Gene Ther., 16:311–319.

29.

Wang

, Calcedo

, Nichols

T.C.

et al. 2005. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood, 105:3079–3086.

30.

Wang

, Wang

, Bell

et al. 2010. Systematic evaluation of AAV vectors for liver directed gene transfer in murine models. Mol. Ther., 18:118–125.

31.

Weitzman

M.D.

, Linden

R.M.

2011. Adeno-associated virus biology. Methods Mol. Biol., 807:1–23.

32.

Yalkinoglu

A.O.

, Heilbronn

, Burkle

et al. 1988. DNA amplification of adeno-associated virus as a response to cellular genotoxic stress. Cancer Res., 48:3123–3129.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.22 MB

0.07 MB

0.09 MB

0.05 MB

0.07 MB

0.06 MB

0.05 MB